Jove
Visualize
Contact Us

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

676
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
676
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

597
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
597
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

606
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
606
Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

2.7K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
2.7K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

792
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
792
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

817
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
817

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teaching Where Life Ends: Peer-Assisted Learning in Hospice as a Model for End-of-Life Nursing Education.

Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association·2025
Same author

Undergraduate Supervised Clinical Practicum Activities: An Enlightening Exploration.

The Journal of nursing education·2022
Same author

Reforming the undergraduate nursing clinical curriculum through clinical immersion: A literature review.

Nurse education in practice·2018
Same author

The flip side of traditional nursing education: A literature review.

Nurse education in practice·2018
Same author

Lessons Learned: Answering the Call to Increase the BSN Workforce.

Journal of professional nursing : official journal of the American Association of Colleges of Nursing·2017
Same author

Nurse's guide to surgical drain removal.

Nursing·2015
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 18, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

615

Cannabinoid hyperemesis syndrome.

Mary C Knowlton1

  • 1Mary C. Knowlton is an associate professor at Western Carolina University in Cullowhee, N.C.

Nursing
|October 1, 2019
PubMed
Summary
This summary is machine-generated.

Cannabinoid hyperemesis syndrome (CHS) causes severe nausea, vomiting, and pain in chronic cannabis users, often relieved by hot baths. This review covers CHS characteristics, causes, treatments, and nursing care.

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

806
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.9K

Related Experiment Videos

Last Updated: Jan 18, 2026

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

615
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

806
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.9K

Area of Science:

  • Gastroenterology
  • Toxicology
  • Pharmacology

Background:

  • Cannabinoid hyperemesis syndrome (CHS) presents with cyclical nausea, vomiting, and abdominal pain.
  • CHS is strongly associated with chronic cannabinoid consumption.
  • Compulsive hot water bathing is a hallmark symptom for relief.

Purpose of the Study:

  • To review the defining characteristics of CHS.
  • To explore proposed pathophysiological mechanisms.
  • To discuss current treatment strategies and nursing implications for CHS patients.

Main Methods:

  • Literature review of studies on cannabinoid hyperemesis syndrome.
  • Synthesis of information regarding clinical presentation, etiology, and management.
  • Analysis of the role of healthcare professionals, particularly nurses, in patient care.

Main Results:

  • CHS is defined by specific symptom clusters and a history of chronic cannabinoid use.
  • Pathophysiology may involve the thermoregulatory and gastrointestinal systems.
  • Treatment primarily involves cessation of cannabinoid use, supportive care, and symptom management.

Conclusions:

  • Understanding CHS is crucial for effective patient management.
  • Nurses play a vital role in patient education, symptom control, and supporting cessation efforts.
  • Further research into CHS pathophysiology and optimized treatments is warranted.